Darren Sherman, President and Chief Operating Officer of Orchestra BioMed Holdings, Inc., filed a Form 4 on November 3, 2026, disclosing the sale of 15,000 shares of common stock on November 2, 2026, under a Rule 10b5-1 trading plan.

Key Highlights

  • Transaction date: 15,000 shares of common stock were disposed of on November 2, 2026.
  • Weighted average price: Shares were sold at a reported weighted average price of $5.74, with individual transactions ranging from $5.66 to $5.995 per share.
  • Post-transaction direct ownership: Sherman directly holds 1,104,402 shares of common stock following the reported transaction.
  • 10b5-1 plan: According to the filing, the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Sherman on December 18, 2025.
  • Indirect holdings: The filing also reports 2,000 shares held indirectly by Sherman's son, for which Sherman disclaims beneficial ownership.
  • Transaction code: The disposal is recorded under transaction code S (sale).

Sherman's Rule 10b5-1 Sale of Orchestra BioMed Common Stock

According to the Form 4 filing, Darren Sherman, who serves as President and Chief Operating Officer of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), disposed of 15,000 shares of common stock (par value $0.0001 per share) on November 2, 2026. The filing indicates that the sales were carried out under a Rule 10b5-1 trading plan that Sherman adopted on December 18, 2025.

The filing reports a weighted average sale price of $5.74 per share. The shares were disposed of in multiple transactions at prices ranging from $5.66 to $5.995 per share. The filing notes that Sherman "undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares disposed at each separate price within the range set forth in this footnote."

Following the reported transaction, the filing states that Sherman directly holds 1,104,402 shares of Orchestra BioMed common stock. Separately, the filing discloses 2,000 shares held indirectly by his son. The filing states that Sherman "disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose." The Form 4 was signed by Andrew Taylor as Attorney-in-Fact on November 3, 2026.

What Was Disclosed

Darren Sherman, President and COO of Orchestra BioMed Holdings, disclosed the sale of 15,000 shares of common stock on November 2, 2026, at a weighted average price of $5.74, executed under a pre-established Rule 10b5-1 trading plan adopted December 18, 2025.